Investors Capital Advisory Services’s Juno Therapeutics, Inc. JUNO Stock Holding History

Investors Capital Advisory Services’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-4,500	Closed	-$239K	–	774
2015 Q2	$239K	Hold	4,500	–	–	0.04%	554
2015 Q1	$272K	Buy	+4,500	New	+$218K	0.05%	493

Other funds holding JUNO

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GAMA

Graticule Asia Macro Advisors New York $1.33B AUM 1,044.61% 1-Year Est. Return

Investors Capital Advisory Services's JUNO Position: Q3 2015 in Review

Investors Capital Advisory Services sold out of Juno Therapeutics, Inc. (JUNO) in Q3 2015, closing a stake of 4,500 shares — an estimated $239K sold.

Investors Capital Advisory Services first reported a position in JUNO in Q1 2015 and held it in 2 quarters. The position peaked at $272K in Q1 2015. 132 funds tracked by Wall St. Rank hold JUNO as of Q3 2015.

Investors Capital Advisory Services reported no remaining Juno Therapeutics, Inc. position as of Q3 2015 after selling out during the quarter.
Investors Capital Advisory Services sold 4,500 Juno Therapeutics, Inc. shares in Q3 2015, an estimated $239K.
Investors Capital Advisory Services first reported a position in Juno Therapeutics, Inc. in Q1 2015 and held it in 2 quarters.
Investors Capital Advisory Services's Juno Therapeutics, Inc. position peaked at $272K in Q1 2015.
132 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q3 2015.

Based on Investors Capital Advisory Services's 13F filing for Q3 2015, filed 17 Nov 2015.